Genetic Signatures Delivers Strong FY25 Growth with Strategic Transformation

Genetic Signatures Ltd (ASX: GSS) reported a strong FY25 performance, with revenue rising 63% to AU$15.9 million, driven largely by robust Australian respiratory sales and growing international traction. Gross margins improved to 55%, while the underlying loss narrowed 28% to AU$12.7 million, reflecting disciplined cost control and streamlined operations. The statutory loss of AU$20.1 million included an AU$7.0 million impairment, following the discontinuation of its Next Generation instrument development in favour of a faster, lower-cost automation pathway.

To this end, GSS has partnered with Tecan Group and Repado Ltd to deliver an integrated, next-generation diagnostic platform, with investment of up to AU$5.0 million over the next two years. Notably, the Company secured its first US commercial contract for the EasyScreen™ Gastrointestinal Parasite Detection Kit, unlocking future growth in a key market. Backed by AU$30.9 million in cash and no debt, GSS has strengthened its business foundations, sharpened its strategic focus, and is well positioned for sustainable global expansion.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com